Psoriasis and Multiple Sclerosis: Is There a Link?

2010 ◽  
Vol 14 (4) ◽  
pp. 151-155 ◽  
Author(s):  
Tiffany Kwok ◽  
Wei Jing Loo ◽  
Lyn Guenther
Keyword(s):  
Multiple Sclerosis ◽  
Case Series ◽  
Cochrane Library ◽  
Review Of The Literature ◽  
T Helper ◽  
Canadian Study ◽  
T Helper 17 ◽  
Increased Risk ◽  
Genetic Linkages ◽  
Interleukin 23

Background: Psoriasis and multiple sclerosis (MS) are both autoimmune T cell-mediated diseases. Some case series have suggested an association. Objective: To investigate the potential relationship between psoriasis and MS based on a systematic review of the literature. Methods: Medline, Cochrane Library, and EMBASE searches were performed. Results: T-helper 17 cells are involved in the pathogenesis of both psoriasis and MS. Both conditions have been associated with interleukin-23 receptor (IL23R) polymorphisms. Studies have reported psoriasis in 0.41 to 7.7% of individuals with MS. A higher rate of psoriasis compared to controls was noted in a few small MS cohorts, but the number of cases was too small to draw any firm conclusions. In two studies, including a large Canadian study of 5,031 patients with MS, there was no increased prevalence of psoriasis in patients over the control population. Family members of individuals with MS do not appear to be at increased risk for psoriasis in these studies. Psoriasis has developed during treatment for MS, and MS has developed during treatment for psoriasis. Conclusion: Although there are some common genetic linkages in psoriasis and MS, psoriasis does not appear to be more common in patients with MS or their relatives.

Z-drugs and Falls: A Focused Review of the Literature

2020 ◽  
Vol 35 (12) ◽  
pp. 549-554
Author(s):  
Nicole Ryba ◽  
Rebecca Rainess
Keyword(s):  
Primary Outcome ◽  
Case Reports ◽  
Inappropriate Medication ◽  
Case Series ◽  
Cochrane Library ◽  
Inpatient Setting ◽  
Care Hospital ◽  
Review Of The Literature ◽  
Increased Risk ◽  
Risk Of Falls

OBJECTIVE: To provide a focused review of the literature related to the association between exposure to Z-drugs and the risk of falls, especially in the older population.<br/> DATA SOURCES: A literature search was conducted using Medline, PsychInfo, and the Cochrane Library database for all clinical trials, case series, and case reports published in English up to May 2020. The search terms used consisted of each Z-drug, including "zolpidem," "zopiclone," "eszopiclone," and "zaleplon," matched with "falls."<br/> STUDY SELECTION: The search yielded 295 studies. After review of abstracts, content and references were reviewed, and duplicates removed, a total of 9 articles met inclusion of exposure to at least 1 Z-drug and a primary outcome of falls.<br/> DATA EXTRACTION: The American Geriatrics Society 2019 Beers Criteria Update for Potentially Inappropriate Medication Use in Older Adults recommends to avoid using nonbenzodiazepine hypnotics in this patient population because of the risk of adverse events.<br/> DATA SYNTHESIS: A majority of the literature suggests an increased risk of falls with exposure to Z-drug use, especially zolpidem. Eight trials examined falls as a primary outcome in non-elderly (n=3) and elderly (n=5) patients in different settings, mostly in an inpatient setting (nursing facility or acute care hospital).<br/> CONCLUSION: Exposure to Z-drugs, especially zolpidem, should be evaluated and counseled on continuously as these medications put patients at an increased risk for falls and other complications.

Z-drugs and Falls: A Focused Review of the Literature

2020 ◽  
Vol 35 (12) ◽  
pp. 549-554
Author(s):  
Nicole Ryba ◽  
Rebecca Rainess
Keyword(s):  
Primary Outcome ◽  
Case Reports ◽  
Inappropriate Medication ◽  
Case Series ◽  
Cochrane Library ◽  
Inpatient Setting ◽  
Care Hospital ◽  
Review Of The Literature ◽  
Increased Risk ◽  
Risk Of Falls

OBJECTIVE: To provide a focused review of the literature related to the association between exposure to Z-drugs and the risk of falls, especially in the older population.<br/> DATA SOURCES: A literature search was conducted using Medline, PsychInfo, and the Cochrane Library database for all clinical trials, case series, and case reports published in English up to May 2020. The search terms used consisted of each Z-drug, including "zolpidem," "zopiclone," "eszopiclone," and "zaleplon," matched with "falls."<br/> STUDY SELECTION: The search yielded 295 studies. After review of abstracts, content and references were reviewed, and duplicates removed, a total of 9 articles met inclusion of exposure to at least 1 Z-drug and a primary outcome of falls.<br/> DATA EXTRACTION: The American Geriatrics Society 2019 Beers Criteria Update for Potentially Inappropriate Medication Use in Older Adults recommends to avoid using nonbenzodiazepine hypnotics in this patient population because of the risk of adverse events.<br/> DATA SYNTHESIS: A majority of the literature suggests an increased risk of falls with exposure to Z-drug use, especially zolpidem. Eight trials examined falls as a primary outcome in non-elderly (n=3) and elderly (n=5) patients in different settings, mostly in an inpatient setting (nursing facility or acute care hospital).<br/> CONCLUSION: Exposure to Z-drugs, especially zolpidem, should be evaluated and counseled on continuously as these medications put patients at an increased risk for falls and other complications.

Vitamin D supplementation could limit T helper-17 response in multiple sclerosis

2014 ◽  
Vol 5 (3) ◽  
pp. 336-339
Author(s):  
Adeleh Najafipoor ◽  
Rasoul Roghanian ◽  
Maryam Rahimi ◽  
Sayyed Hamid Zarkesh-Esfahani ◽  
Vahid Shayegannejad
Keyword(s):  
Multiple Sclerosis ◽  
Vitamin D ◽  
Vitamin D Supplementation ◽  
T Helper ◽  
T Helper 17

scholarly journals Original article Clinical and neuroimaging correlation of movement disorders in multiple sclerosis: case series and review of the literature

2014 ◽  
Vol 1 ◽  
pp. 92-100 ◽  
Author(s):  
Anna Potulska-Chromik ◽  
Monika Rudzinska ◽  
Monika Nojszewska ◽  
Aleksandra Podlecka-Piętowska ◽  
Andrzej Szczudlik ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Movement Disorders ◽  
Case Series ◽  
Review Of The Literature ◽  
Multiple Sclerosis Case

scholarly journals Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis

2019 ◽  
Vol 9 ◽  
Author(s):  
Andrea Iannello ◽  
Simona Rolla ◽  
Alessandro Maglione ◽  
Giulio Ferrero ◽  
Valentina Bardina ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Regulatory Cells ◽  
Regulatory Cells ◽  
T Helper ◽  
T Helper 17

scholarly journals A Systematic Review of the Literature on Early Vocalizations and Babbling Patterns in Young Children

2018 ◽  
Vol 40 (1) ◽  
pp. 3-14 ◽  
Author(s):  
Lydia Morgan ◽  
Yvonne E. Wren
Keyword(s):  
Systematic Review ◽  
Case Series ◽  
Speech Development ◽  
Cochrane Library ◽  
Bibliographic Databases ◽  
Review Of The Literature ◽  
Phonological Acquisition ◽  
Future Studies ◽  
The Cochrane Library ◽  
Children's Speech

Children’s speech development begins in infancy. The pattern of this development has been explored in studies over a number of years using a range of research methodology and approaches to investigation. A systematic review of the existing literature was carried out to determine the collective contribution of this literature to our understanding of early vocalizations and babbling through the period 9 to 18 months. Eight bibliographic databases were searched as well as the Cochrane library. Thirteen studies were identified for inclusion, which were mostly longitudinal observational case series. The review identified progressive increases in the complexity and volume of infants’ early vocalizations through the period. It also found a broad order of phonological acquisition. Although the studies in this review demonstrated marked individual variation, the review provides indicative patterns of development which can be used as a basis to explore relationships with later speech development in future studies.

scholarly journals Fenofibrate Inhibited the Differentiation of T Helper 17 CellsIn Vitro

PPAR Research ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Zhou Zhou ◽  
Weiliang Sun ◽  
Ying Liang ◽  
Yanxiang Gao ◽  
Wei Kong ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Autoimmune Diseases ◽  
Th17 Cells ◽  
Transforming Growth Factor ◽  
Inflammatory Diseases ◽  
Lipid Lowering ◽  
Interleukin 17 ◽  
T Helper ◽  
T Helper 17 ◽  
Th17 Differentiation

Uncontrolled activity of T cells mediates autoimmune and inflammatory diseases such as multiple sclerosis, inflammatory bowel diseases, rheumatoid arthritis, type 1 diabetes, and atherosclerosis. Recent findings suggest that enhanced activity of interleukin-17 (IL-17) producing T helper 17 cells (Th17 cells) plays an important role in autoimmune diseases and inflammatory diseases. Previous papers have revealed that a lipid-lowering synthetic ligand of peroxisome proliferator-activated receptorα(PPARα), fenofibrate, alleviates both atherosclerosis and a few nonlipid-associated autoimmune diseases such as autoimmune colitis and multiple sclerosis. However, the link between fenofibrate and Th17 cells is lacking. In the present study, we hypothesized that fenofibrate inhibited the differentiation of Th17 cells. Our results showed that fenofibrate inhibited transforming growth factor-β(TGF-β) and IL-6-induced differentiation of Th17 cellsin vitro. However, other PPARαligands such as WY14643, GW7647 and bezafibrate did not show any effect on Th17 differentiation, indicating that this effect of fenofibrate might be PPARαindependent. Furthermore, our data showed that fenofibrate reduced IL-21 production and STAT3 activation, a critical signal in the Th17 differentiation. Thus, by ameliorating the differentiation of Th17 cells, fenofibrate might be beneficial for autoimmunity and inflammatory diseases.

scholarly journals Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans

2008 ◽  
Vol 226 (1) ◽  
pp. 112-131 ◽  
Author(s):  
Lyudmila Lyakh ◽  
Giorgio Trinchieri ◽  
Lisa Provezza ◽  
Giuseppe Carra ◽  
Franca Gerosa
Keyword(s):  
Interleukin 12 ◽  
T Helper ◽  
T Helper 17 ◽  
Interleukin 23
Sign in / Sign up

Export Citation Format

Share Document